This appeal was not successful at this stage
The AAO dismissed the appeal, agreeing with the Director that although the Beneficiary met two of the six evidentiary criteria, the totality of the evidence did not establish that he is internationally recognized as outstanding in the field of pharmaceutical science.
A research and development company petitioned to classify its senior scientist as an outstanding researcher in pharmaceutical sciences under EB-1B. The Nebraska Service Center Director denied the petition after concluding that the Beneficiary, while meeting the scholarly articles and original contributions criteria, had not demonstrated international recognition as outstanding. On de novo review, the AAO agreed, finding that the articles cited as 'about' the Beneficiary were actually about other researchers' work, that the comparative citation data was misrepresented, that graduate-level travel awards did not establish international recognition, and that expert letters showed potential future impact rather than existing international recognition. The appeal was dismissed.
What worked: The Beneficiary successfully met two of the six EB-1B evidentiary criteria: authorship of scholarly articles in the field and evidence of original contributions to pharmaceutical science, including expert letters and citation records showing other researchers building on his work.
What failed: Articles about the field that merely cited the Beneficiary's work were incorrectly characterized as being 'about' him and did not satisfy the published-material criterion. Comparative citation data relied on a misread Norwegian study that measured publication rates, not citation benchmarks for pharmaceutical researchers. Graduate-level travel awards to national conferences did not establish international recognition. Expert letters praised the potential of the Beneficiary's research but did not show it had already achieved international recognition as outstanding.
Takeaway: For EB-1B petitions, it is not enough to show that a researcher's work is promising or contributes to the field — petitioners must demonstrate that the researcher's contributions have already been internationally recognized as outstanding, using comparative benchmarks and media coverage that directly features the beneficiary rather than merely citing their work.
Cases like this are frequently used by attorneys when responding to RFEs or building initial petitions. The evidence patterns that worked (or failed) here directly reflect what USCIS officers look for when evaluating EB-1B criteria.
● Evidence that moved the needle
- The Beneficiary successfully met two of the six EB-1B evidentiary criteria: authorship of scholarly articles in the field and evidence of original contributions to pharmaceutical science, including expert letters and citation records showing other researchers building on his work.
● Evidence that wasn't enough alone
- Articles about the field that merely cited the Beneficiary's work were incorrectly characterized as being 'about' him and did not satisfy the published-material criterion
- Comparative citation data relied on a misread Norwegian study that measured publication rates, not citation benchmarks for pharmaceutical researchers
- Graduate-level travel awards to national conferences did not establish international recognition
- Expert letters praised the potential of the Beneficiary's research but did not show it had already achieved international recognition as outstanding.
Authorship of scholarly articles satisfied one of the two required evidentiary criteria
Original contributions to pharmaceutical science satisfied one of the two required evidentiary criteria
Expert reference letters confirming importance of Beneficiary's research in mRNA and related areas
Google Scholar citation records showing other researchers building upon the Beneficiary's published work
Five articles submitted in response to the RFE were not 'about' the Beneficiary but were about the authors' own work or broader field reviews, with only brief citations to the Beneficiary's findings
Norwegian publication-rate article was mischaracterized as providing citation-rate benchmarks; it actually measured publication rates of Norwegian Ph.D. students, not citations across all pharmaceutical researchers
Travel awards to national conferences were awarded to graduate students and did not establish international recognition as outstanding
Argument that the Beneficiary is one of a small group of mRNA scientists was rejected as irrelevant to international recognition; skill shortages are a Department of Labor matter
Expert letters established potential future impact and originality but did not demonstrate that contributions have already achieved international recognition as outstanding
Completed
I-140 filed
Senior scientist conducting research in pharmaceutical sciences, specializing in mRNA process development and cell/gene therapy raw materials
Completed
Director — Denied
Initial decision: Denied.
Completed
Appeal to the AAO
Petitioner appealed to the Administrative Appeals Office for de novo review.
2019-01-18
AAO decision — Dismissed
The AAO dismissed the appeal, agreeing with the Director that although the Beneficiary met two of the six evidentiary criteria, the totality of the evidence did not establish that he is internationally recognized as outstanding in the field of pharmaceutical science.
If you're appealing a similar decision, I-290B must be filed within 30 days of personal service of the denial, or 33 days if mailed.
Find this useful? A coffee helps keep Case Reviewer free and ad-free.
Buy me a coffee